This clinical trial is worth considering. Patients who initially receive placebo (inactive sugar pill) will at a certain point in the study be switched over to active drug, LY450139. This means every participant gets the drug. Additionally, all patients who complete this study will have the option to continue receiving LY450139 by participating in an open label study.This means you can continue receiving the drug free of charge after participation in the clinical trial.
LY450139 is being tested to see if it can slow the progression associated with Alzheimer's disease by inhibiting gamma-secretase, an enzyme that can create a sticky protein called amyloid beta. Slowing the rate of disease progression could preserve independent functioning and quality of life for Alzheimer's patients in the milder stages of the disease, potentially delaying the onset of the severe stages of the disease.
Sunday, October 05, 2008
Read the complete article at the Alzheimer's Reading Room